2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 21:43, 2 December 2023
, 2 December 2023→Clinical Trials
| Line 328: | Line 328: | ||
|- | |- | ||
|{{pmid text|35821806}} | |{{pmid text|35821806}} | ||
|[[RCT]], 60 days | |||
* placebo (n=31) | |||
* 300mg (n=31) | |||
| | | | ||
* 66 healthy subjects | |||
* age 40-65 | |||
| | | | ||
* NAD+ levels increase by 11.3% after 30 days, 38% after 60 days | |||
|- | |- | ||
|{{pmid text|34912838}} | |{{pmid text|34912838}} | ||